NEWHALL CHARLES W III sold 7.6% of their position (10.70K shares) of SUPERNUS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $387.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 11/12/2024ACC: 0001628280-24-047155
Director
Since Feb 2026
-10.70K
Net shares
Net seller
$387.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
20K acquired · 30.70K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+20K
Price / share
$9.13
Trade value
$182.60K
% of position
16.5%
11/11/2024
120.97K→140.97K
Common Stock
Direct
Shares
−10.70K
Price / share
$36.24
Trade value
$387.77K
% of position
7.6%
11/11/2024
140.97K→130.28K
Total
Net shares
+9.30K
Net value
-$205.17K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 11/11/2024 | M · Option Exercise | +20K | $9.13 | $182.60K | 16.5% | 120.97K | 140.97K |
| Common Stock Direct | 11/11/2024 | S · Sale | −10.70K | $36.24 | $387.77K | 7.6% | 140.97K | 130.28K |
| Total | +9.30K | -$205.17K | ||||||
Derivative Transactions1
Director Stock Option (Right to Buy)
Direct
Converts to
Common Stock
20K shares
Shares
−20K
Strike price
9.13
Held after
0.00
Exercisable
—
11/11/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy) Direct | Common Stock20K shares | 11/11/2024 | M · Option Exercise | −20K | 9.13 | — | 0.00 |